Table 2.
Oncological Outcomes in the 5 Included Studies
| Study Reference | Local Recurrence | Regional Recurrence | Metastasis | Mortality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PF Preservation | PF Removal | P | PF Preservation | PF Removal | P | PF Preservation | PF Removal | P | PF Preservation | PF Removal | P | |
| Dalberg et al14; | n = 16 (12.8%) | n = 8 (6.6%) | 0.09 | n = 8 (6.4%) | n = 8 (6.6%) | 0.99 | n =30 (24.0%) | n = 28 (23.0%) | 0.73 | n = 35 (28.0%) | n = 28 (23.0%) | 0.37 |
| Dalberg et al15 | n = 18 (14.6%) | n = 10 (8.3%) | 0.12 | n = 7 (5.7%) | n = 8 (6.6%) | 0.82 | n = 39 (31.7%) | n = 35 (28.9%) | 0.61 | n = 53 (43.1%) | n = 47 (38.8%) | 0.47 |
| Abdelhamid et al10 | n = 0 (0.0%) | n = 0 (0.0%) | 1.0 | — | — | — | — | — | — | — | — | — |
| Sandelin et al16 | n = 9 (4.4%) | — | — | n = 5 (2.5%) | — | — | — | — | n = 31 (15.4%) | — | — | |
| Salgarello et al13 | n = 2 (1.1%) | — | — | — | — | — | — | — | — | — | — | — |